Antares Pharma, Inc. (ATRS)

R&D Expense Growth

43.29%

Fiscal year · Period ending:

ATRS logo

ATRS R&D Expense Growth

Latest reported43.29%
ATRS FY R&D Growth (YoY) (0.00% → 43.29%)
High-resolution chart · PNG

ATRS r&d expense growth history

Annual fiscal periods. Dates are reporting period ends; fiscal years can differ from calendar years.

Antares Pharma, Inc. R&D Expense Growth — Annual fiscal periods
Period endingR&D Expense Growth
43.2862%
-4.7346%
-13.8222%
-6.2296%
-37.7714%
7.0718%
5.8673%
22.1094%
2.2908%
122.7322%
-23.8929%
11.389%
0.4575%
46.7003%
41.917%
10.8222%
-3.8617%
1.5018%
-4.3884%
2.7689%
190.742%
-49.415%
-31.2517%
36.6399%
-0.4253%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.